Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Monitoring of specific immunotherapy in children allergic to hymenoptera venom by improved basophil activation test (CROSBI ID 676155)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Živković, J., Zenić, L., Bulat Lokas, S., Nogalo, B., Turkalj, M., Polančec, D. Monitoring of specific immunotherapy in children allergic to hymenoptera venom by improved basophil activation test. 2018

Podaci o odgovornosti

Živković, J., Zenić, L., Bulat Lokas, S., Nogalo, B., Turkalj, M., Polančec, D.

engleski

Monitoring of specific immunotherapy in children allergic to hymenoptera venom by improved basophil activation test

Introduction: The most effective way of preventing severe allergic reactions caused by hymenoptera venom is specific immunotherapy (SIT). Although serum specific IgE and skin prick test are most often used diagnostic methods in allergies, they do not provide a real predictive value after immunotherapy, especially when the test is performed a year after the last allergic reaction. Basophil activation test (BAT) is used as a functional test to monitor basophil activation upon in vitro allergen challenge by detecting the expression of membrane surface markers. Although different studies have shown that CD63 is the most promising basophil activation and degranulation marker, we decided to used it in combination with CD203c, which allowed us to separately monitor basophil activation and degranulation. Methods: Peripheral blood samples of children allergic to hymenoptera venom were prepared using the FlowCAST® (Bühlmann, Switzerland) CCR3/CD63 staining protocol, with the addition of the antibodies against CD45 and CD203c. Blood was drawn before starting SIT and one year after the first treatment. Log dilutions of hymenoptera venom allergen ranging from 10μg/ml to 10 pg/ml final concentration were made. Acquisition of the samples was performed using the Navios flow cytometer (Beckman Coulter, USA) and the data were analysed using the FlowLogic™ software (Inivai Technologies, Australia). The percentage of activated basophils and the mean fluorescence intensity (MFI) for all markers was determined. Results: There was an up-regulation of CD203c among samples treated with different allergen concentrations even when there was no up- regulation of CD63, i.e. the differences in CD203c expression were observed during non-degranulating stimulation of basophils. Also, there was a simultaneous decrease in CD63 and CD203c expression one year after SIT, indicating a development of tolerance to hymenoptera venom. Conclusion: The use of CD203c, together with CD45 and CD63/CCR3 improves sensitivity of BAT and enables determination of the activated/non- degranulated and activated/degranulated basophils. This kind of an improved BAT has become important in diagnosis of allergy to insect venom at our hospital, allowing us to distinguish between allergic and sensitized patients with additional benefit in monitoring of SIT. Our results imply that BAT might impose a promising diagnostic tool for predicting the outcome of immunotherapy, allowing a better optimization of the treatment and reduction of the potential harmful

SIT, BAT, Allergic reaction

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

2018.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Podaci o skupu

33rd Congress of the International Society for Advancement of Cytometry

poster

28.04.2018-02.05.2018

Prag, Češka Republika

Povezanost rada

Kliničke medicinske znanosti